4 research outputs found
Programmed cell death as a prognostic indicator for radiation therapy in cervical carcinoma patients: A pilot study
Purpose : In clinical practice, radiation therapy often fails in
cervical carcinoma stage IIIB and there is a need to develop a
predictive assay for prognosis of radiation treatment outcome in cancer
patient. We have attempted to evaluate the relevance of changes in
Membrane Fluidity (MF) and associated apoptotic cell death in cervical
cancer cells after first fractionated dose of radiation therapy to
treatment outcome of stage IIIB cervical carcinoma patients. Materials
and Methods: Biopsies of 15 patients with histologically proven cervix
cancer were collected from the patients before and 24 h after first
fractionated radiation dose of 2 grays (Gy). Cell suspension made in
Dulbecco\u2032s Modified Eagle\u2032s Medium (DMEM) were used for
further investigations and cell suspension of cervix cancer patient
were used to measure MF by fluorescence polarization method and
apoptotic index (AI) was determined by Tdt dUTP Nucleotide End Labeling
(TUNEL) assay. Results: A substantial increase in MF and AI was
observed in cervical cancer cells irradiated ex vivo . A significant
correlation ( P < 0.001) was found between the changes in AI after
first fractionated dose of radiotherapy and treatment outcome of
patients. No significant correlation ( P > 0.1) was detected between
changes in MF and treatment outcome of patients. Conclusion:
Preliminary results showed significant change in MF and a marked
increase in percentage apoptosis of cervix cancer cells irradiated ex
vivo . The changes in AI after first fractionated dose of radiotherapy
in cervical carcinoma patients may provide a predictor of prognosis for
radiotherapy in uterine cervical carcinoma patients
A phase I trial of tocoferol monoglucoside in patients undergoing hemi-body radiation
Purpose : To evaluate Tocoferol monoglucoside (TMG), a water soluble
vit. E. in a phase I trial, as a radiation protector in those
undergoing hemi-body radiation for disseminated disease. Materials and
Methods: Patients scheduled to receive modified hemi-body radiation
were accrued for the study. Patients not only had disseminated skeletal
disease but, were heavily pretreated Seven patients were accrued for
the study. Patients received 1 and 2 gms of TMG. 30-40 minutes before
hemibody radiation. A dose of 600 cGy was delivered on telecobalt
equipment at mid plane. Immediate Toxicities were evaluated as well as
response to pain. Results: All the seven patients underwent radiation
uneventfully. There was no drug related toxicity. Pain relief was
adequate. Conclusion: Tocoferol monoglucoside an effective antioxidant
with no significant acute toxicity, when administered in a dose of 1 or
2 gms per oral route. TMG being water-soluble can have global
antioxidant and radio protective effects. This needs further clinical
evaluation